Proteins and nucleic acids useful in vaccines targeting
Disclosed are novel immunogenic proteins derived from Staphylococcus aureus , as well as methods for their use in conferring protective immunity against S. aureus infections. Also disclosed are nucleic acids encoding the proteins and methods of use of these nucleic acids.
1. A pharmaceutical composition consisting of at least one polypeptide and a pharmaceutically acceptable carrier, vehicle or diluent, and an immunological adjuvant, wherein the at least one polypeptide consists of 35-144 contiguous amino acid residues from amino acid residues 343-486 of SEQ ID NO: 9.
2. The pharmaceutical composition according to claim 1 , wherein the at least one polypeptides consists of amino acid residues 343-452 of SEQ ID NO: 9.
3. A pharmaceutical composition consisting of
at least one polypeptide, and
a pharmaceutically acceptable carrier, vehicle or diluent, and an immunological adjuvant, wherein the at least one polypeptide consists of an amino acid sequence that has at least 80% sequence identity with 35-144 contiguous amino acids from amino acid residues 343-486 of SEQ ID NO: 9.
4. The pharmaceutical composition according to claim 1 , wherein said at least one polypeptide is a single polypeptide.
5. The pharmaceutical composition according to claim 3 , wherein said at least one polypeptide is a single polypeptide.
6. The pharmaceutical composition according to claim 3 , wherein said at least one polypeptide consists of an amino acid sequence that has at least 80% sequence identity with 35-144 contiguous amino acids from amino acid residues 343-452 of SEQ ID NO: 9.
7. The pharmaceutical composition according to claim 1 , wherein the immunological adjuvant is an aluminium based adjuvant.
8. The pharmaceutical composition according to claim 2 , wherein the immunological adjuvant is an aluminium based adjuvant.
9. The pharmaceutical composition according to claim 3 , wherein the immunological adjuvant is an aluminium based adjuvant.